A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial-Reference-Cited by-同舟云学术

A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial

Published:2005-02 Issue:3 Volume:41 Page:398-403
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Ducreux M.,Van Cutsem E.,Van Laethem J.L.,Gress T.M.,Jeziorski K.,Rougier P,Wagener T.,Anak O.,Baron B.,Nordlinger B.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference20 articles.

1. Cancer of the liver and biliary tree;Fong,2001

2. Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study;Taal;Ann Oncol,1993

3. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer;Falkson;Cancer,1984

4. Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas;Takada;Oncology,1994

5. A phase II study of cisplatin in patients with biliary tract carcinoma;Okada;Oncology,1994

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Durable Response to Pembrolizumab and Lenvatinib in a Patient with Chemotherapy-refractory Cholangiocarcinoma;Archives of Cancer Science and Therapy;2024-07-15

2. A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma;The Oncologist;2022-02-19

3. Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma;Liver Cancer;2022

4. Gallbladder cancer: Historical treatment and new management options;World Journal of Gastrointestinal Oncology;2021-10-15

5. Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway;Biomedicines;2021-07-24